Skip to main content
SpringerLink
Log in

Ovarian tumors of low malignant potential

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Ovarian tumors of low malignant potential (LMP) differ from epithelial ovarian carcinoma in etiology, molecular biology, and prognosis. LMP tumors are not precursor lesions to ovarian carcinoma. Treatment is primarily surgical. Women found to have an ovarian tumor of LMP should undergo removal of the involved adnexa; surgical staging; and cytoreductive surgery. Women in the reproductive years should be given the option of conservative surgery, preserving the contralateral adnexa and uterus. There is no proven benefit to adjuvant chemotherapy or radiotherapy after primary surgery. In most cases, the diagnosis of an ovarian tumor of LMP conveys good prognosis, with excellent long-term survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Prat J: Ovarian tumors of borderline malignancy (tumors of low malignant potential): a critical appraisal. Adv Anat Pathol 1999, 6:247–274. Comprehensive review of the various histopathologic entities previously classified as ovarian tumors of LMP.

    Article  PubMed  CAS  Google Scholar 

  2. Gershenson DM, Silva EG, Levy L, et al.: Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 1998, 82:1096–1103.

    Article  PubMed  CAS  Google Scholar 

  3. Burks RT, Sherman ME, Kurman RJ: Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 1996, 20:1319–1330.

    Article  PubMed  CAS  Google Scholar 

  4. Eichhorn JH, Bell DA, Young RH, et al.: Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol 1999, 23:397–409.

    Article  PubMed  CAS  Google Scholar 

  5. Dietel M, Hauptmann S: Serous tumors of low malignant potential of the ovary. I. Diagnostic pathology. Virchows Arch 2000, 436:403–412.

    Article  PubMed  CAS  Google Scholar 

  6. Ronnett BM, Shmookler BM, Sugarbaker PH, et al.:Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997, 2:197–226.

    PubMed  CAS  Google Scholar 

  7. Riopel MA, Ronnett BM, Kurman RJ: Evaluation of diagnostic criteria and behavior of ovarian intestinaltype mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol 1999, 23:617–635.

    Article  PubMed  CAS  Google Scholar 

  8. Lawrence WD: The borderland between benign and malignant surface epithelial ovarian tumors. Current controversy over the nature and nomenclature of ’borderline’ ovarian tumors. Cancer 1995, 76(suppl):2138–2142.

    Article  PubMed  CAS  Google Scholar 

  9. Gotleib WH, Friedman E, Bar-Sade RB: Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998, 90:995–1000.

    Article  Google Scholar 

  10. Lu KH, Cramer DW, Muto MG: A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 1999, 93:34–37.

    Article  PubMed  CAS  Google Scholar 

  11. Harris R, Whittemore AS, Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992, 136:1204–1211.

    PubMed  CAS  Google Scholar 

  12. McCluskey LL, Dubeau LL: Biology of ovarian cancer. Curr Opin Oncol 1997, 9:465–470. Review article that sets out the molecular evidence which distinguishes LMP tumors from epithelial ovarian carcinoma.

    Article  PubMed  CAS  Google Scholar 

  13. Lu KH, Bell DA, Welch WR, et al.: Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998, 58:2328–2330.

    PubMed  CAS  Google Scholar 

  14. Caduff RG, Svoboda-Newman SM, Ferguson AW, et al.:Comparison of mutations of Ki-ras and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999, 23:323–328.

    Article  PubMed  CAS  Google Scholar 

  15. Evans MR, McDicken IW, Herrington CS, et al.:Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumors. J Pathol 1999, 189:53–59.

    Article  PubMed  CAS  Google Scholar 

  16. Bjorge T, Engeland A, Hansen S, et al.: Prognosis of patients with ovarian cancer and borderline tumors diagnosed in Norway between 1954 and 1993. Int J Cancer 1998, 75:663–670. Long-term population-based follow-up data on LMP tumors.

    Article  PubMed  CAS  Google Scholar 

  17. Seidman JD, Kurman RJ: Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol 2000, 31:539–557. Meta-analysis of 97 studies including 4129 women with serous tumors of LMP.

    Article  PubMed  CAS  Google Scholar 

  18. Yeo EL, Yu KM, Poddar MC, et al.: The accuracy of intraoperative frozen section in the diagnosis of ovarian tumors. J Obstet Gynaecol Res 1998, 24:189–915.

    Article  PubMed  CAS  Google Scholar 

  19. Houck K, Nikrui N, Duska L, et al.: Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis. Obstet Gynecol 2000, 95:839–843.

    Article  PubMed  CAS  Google Scholar 

  20. Kayicioglu F, Pata O, Cengiz S, et al.: Accuracy of frozen section diagnosis in borderline ovarian malignancy. Gynecol Obstet Invest 2000, 49:187–189.

    Article  Google Scholar 

  21. Darai E, Teboul J, Fauconnier A, et al.: Management and outcome of borderline ovarian tumors incidentally discovered at or after laparoscopy. Acta Obstet Gynecol Scand 1998, 77:451–457.

    Article  PubMed  CAS  Google Scholar 

  22. Malik E, Bohm W, Stoz F, et al.: Laparoscopic management of ovarian tumors. Surg Endosc 1998, 12:1326–1333.

    Article  PubMed  CAS  Google Scholar 

  23. Ulrich U, Paulus W, Schneider A, et al.: Laparoscopic surgery for complex ovarian masses. J Am Assoc Gynecol Laparosc 2000, 7:373–380.

    Article  PubMed  CAS  Google Scholar 

  24. Liu PS, Gershenson DM, Bevers MW, et al.: The current status of surgical staging of ovarian serous borderline tumors. Cancer 1999, 85:905–911.

    Article  Google Scholar 

  25. Gershenson DM, Silva EG, Tortolero-Luna G, et al.:Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 1998, 83:2157–2163.

    Article  PubMed  CAS  Google Scholar 

  26. Kaern J, Trope CG, Abeler VM, et al.: A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities. Cancer 1993, 71:1810–1820.

    Article  PubMed  CAS  Google Scholar 

  27. Morris RT, Gershenson DM, Silva EG, et al.: Outcome and reproductive function after conservative surgery for borderline ovarian tumors. Obstet Gynecol 2000, 95:541–547.

    Article  PubMed  CAS  Google Scholar 

  28. Gotlieb WH, Flikker S, Davidson B, et al.: Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome. Cancer 1998, 82:141–146.

    Article  PubMed  CAS  Google Scholar 

  29. Barnhill DR, Kurman RJ, Brady MF, et al.: Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clin Oncol 1995, 13:2752–2756.

    PubMed  CAS  Google Scholar 

  30. Barakat RR, Benjamin I, Lewis JL Jr, et al.: Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential. Gynecol Oncol 1995, 59:390–393.

    Article  PubMed  CAS  Google Scholar 

  31. Trope C, Kaern J, Vergote I, et al.: Are borderline tumors of the ovary overtreated both surgically and system-ically: a review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol 1993, 51:236–243.

    Article  PubMed  CAS  Google Scholar 

  32. Gershenson DM, Deavers M, Diaz S, et al.: Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 1999, 5:4053–4058.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Cancer Institute, 6130 Executive Boulevard, Suite 741, MSC 7436, 20892-7436, Bethesda, MD, USA

    Edward L. Trimble MD, MPH

  2. The Johns Hopkins Hospital, 600 N. Wolfe Street, 21287, Baltimore, MD, USA

    Edward L. Trimble MD, MPH & Cornelia L. Trimble MD

Authors
  1. Edward L. Trimble MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelia L. Trimble MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Trimble, E.L., Trimble, C.L. Ovarian tumors of low malignant potential. Curr. Treat. Options in Oncol. 2, 103–108 (2001). https://doi.org/10.1007/s11864-001-0052-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-001-0052-2

Keywords

Search

Navigation